The Evolution of GLP-1 Agonists: From Single to Multi-Receptor Therapies To overcome the limitations of GLP-1 monotherapy, newer pharmacologic strategies have focused on multi-receptor incretin agonism
Collectively, these results indicate that the inhibition of intestinal FXR signaling by non-12-OH FXR-antagonistic BAs is critically involved in the regulation of GLP-1 production, insulin secretion, and glucose homeostasis by T3
doi: 10.1007/5584_2020_496 75 NauckMAQuastDRWefersJMeierJJ
It started with the three Mile Island Paul Walsh: Yeah
also, lipids and C-reactive protein levels increased by week 120, yet maintaining a significant difference with respect to patients on placebo 77
Recent studies have expanded the application of SP via intravenous injection for magnetic actuation and cargo delivery 20,23,24 , which demonstrated its biocompatibility and biosafety as an intravenous medication